An Australian multicentre prospective randomised study to compare the safety and efficacy of intravenous immunoglobulin replacement therapy with subcutaneous immunoglobulin replacement therapy (Hizentra) to treat acquired hypogammaglobulinaemia in patients with chronic lymphocytic leukaemia (CLL)
Latest Information Update: 11 Dec 2019
At a glance
- Drugs Immune globulin (Primary) ; Immune globulin
- Indications Agammaglobulinaemia
- Focus Therapeutic Use
- 10 Dec 2019 Status changed from recruiting to discontinued.
- 01 Nov 2017 Status changed from not yet recruiting to recruiting.
- 17 Jul 2017 New trial record